View Older Stories View More Recent Stories

Jul 24, 2017 08:35AM Delmar Pharma (DMPI) Announces Approval from China's HGRAC to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM
Jul 24, 2017 08:30AM DelMar Pharmaceuticals Receives Approval from China's Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM
Jul 18, 2017 08:31AM Delmar Pharma (DMPI) Completes 1st Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM
Jul 18, 2017 08:30AM DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM
Jul 11, 2017 08:35AM Delmar Pharma (DMPI) Names Dr. Erich Mohr as Chairman; Saiid Zarrabian Joins Board
Jul 11, 2017 08:30AM DelMar Pharmaceuticals Appoints Saiid Zarrabian to the Board of Directors and Names Dr. Erich Mohr as Chairman
Jun 29, 2017 08:30AM DelMar Pharmaceuticals Joins National Brain Tumor Society's Research Roundtable
Jun 22, 2017 08:30AM DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM
Jun 16, 2017 08:32AM Delmar Pharma (DMPI) Presents Poster of Clinical Research with VAL-083 in Patients with Chemo-resistant GBM
Jun 16, 2017 08:30AM DelMar Presents Poster of Clinical Research with VAL-083 in Patients with Chemo-resistant Glioblastoma ("GBM") at SNO's Pediatric Neuro-Oncology Basic and Translational Research Conference
May 18, 2017 05:13PM DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2017 Financial Results
May 11, 2017 08:35AM Delmar Pharma (DMPI) Formalizes Collaboration with PRA Health (PRAH) for Phase 3 Trial of VAL-083 in GBM
May 11, 2017 08:30AM DelMar Formalizes Collaboration with PRA Health Sciences for Phase 3 Trial of VAL-083 in Recurrent Glioblastoma Multiforme (GBM)
May 8, 2017 08:41AM Delmar Pharma (DMPI) Presents New Mechanism of Action Data for VAL-083 in Temozolomide-Resistant GBM at WFNOS
May 8, 2017 08:30AM DelMar Presents New Mechanism of Action Data for its Lead Agent VAL-083 in Temozolomide-Resistant Glioblastoma Multiforme (GBM) at the World Federation of Neuro-Oncology Societies (WFNOS)
Apr 21, 2017 08:30AM DelMar Pharmaceuticals Announces Closing Of $9,000,000 Public Offering Of Common Stock And Warrants
Apr 13, 2017 08:18AM Delmar Pharma (DMPI) Prices $9M Common Stock and Warrant Offering
Apr 13, 2017 08:16AM DelMar Pharmaceuticals Announces Pricing Of $9,000,000 Public Offering Of Common Stock And Warrants
Apr 12, 2017 04:25PM Delmar Pharma (DMPI) to Offer Common Stock and Warrants
Apr 12, 2017 04:22PM DelMar Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrants
Apr 5, 2017 08:36AM Delmar Pharma (DMPI) Provides VAL-083 Updates from AACR Meeting
Apr 5, 2017 08:30AM DelMar Pharmaceuticals Provides VAL-083 Updates from the Ongoing American Association for Cancer Research (AACR) Annual Meeting
Mar 28, 2017 08:32AM Delmar Pharma (DMPI) Announces Abstract Presentations for AACR
Mar 28, 2017 08:30AM DelMar Pharmaceuticals Announces Abstract Presentations for the American Association for Cancer Research (AACR) Annual Meeting in April 2017
Feb 13, 2017 08:42AM Delmar Pharma (DMPI) Doses First Patient in Phase Two Trial of VAL-083 for MGMT-unmethylated Recurrent GBM
Feb 13, 2017 08:40AM DelMar Pharmaceuticals Announces Dosing of the First Patient in Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)
Feb 13, 2017 08:15AM DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2017 Financial Results
Jan 25, 2017 08:31AM Delmar Pharma (DMPI), MD Anderson Initiate New Phase Two Trial of VAL-083 for MGMT-unmethylated Recurrent GBM
Jan 25, 2017 08:30AM DelMar Pharmaceuticals and MD Anderson Initiate New Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)
Jan 9, 2017 08:30AM DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding from the Government of Canada to Support Expanded Research with Lead Product Candidate VAL-083
Dec 14, 2016 08:00AM DelMar Pharmaceuticals Receives Notice of Allowance from the US Patent and Trademark Office for Key Patent for VAL-083
Nov 21, 2016 08:30AM DelMar Pharmaceuticals Delivers an Address and Presents an Overview of Upcoming GBM Trials with VAL-083 at the CNS Anticancer Drug Discovery Development Conference and Society for NeuroOncology Annual
Nov 14, 2016 08:30AM DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2017 Financial Results and Corporate Update
Nov 7, 2016 08:30AM DelMar Pharmaceuticals Presents New VAL-083 Data at Two International Scientific Conferences
Oct 17, 2016 08:30AM DelMar Pharmaceuticals Presents Overview of VAL-083's Unique Anticancer Mechanism at the European Association of Neuro-Oncology (EANO) Annual Meeting
Oct 13, 2016 08:30AM DelMar Pharmaceuticals Announces Upcoming Scientific Conference Presentations
Sep 13, 2016 08:31AM Delmar Pharma (DMPI) Announces Presentation of Positive VAL-083 Data as Ovarian Cancer Treatment
Sep 13, 2016 08:30AM DelMar Pharmaceuticals Presents Data Supporting the Potential of VAL-083 as a New Treatment for Ovarian Cancer at the 11th Biennial Ovarian Cancer Research Symposium
Sep 7, 2016 08:37AM Delmar Pharma (DMPI), Accurexa Enter Brain Cancer Therapy-Focused Collaboration
Sep 7, 2016 08:30AM DelMar Pharmaceuticals and Accurexa to Collaborate in the Development of a Novel Combination Chemotherapy for the Local Treatment of Brain Cancer
Sep 7, 2016 08:30AM DelMar Pharmaceuticals and Accurexa to Collaborate in the Development of a Novel Combination Chemotherapy for the Local Treatment of Brain Cancer
Aug 30, 2016 08:30AM DelMar Pharmaceuticals to Present at the 18th Annual Rodman & Renshaw Global Investment Conference on September 13, 2016
Aug 30, 2016 08:30AM DelMar Pharmaceuticals to Present at the 18th Annual Rodman & Renshaw Global Investment Conference on September 13, 2016
Aug 11, 2016 08:30AM DelMar Pharmaceuticals to Present at the 11th Biennial Ovarian Cancer Research Symposium
Jul 21, 2016 08:30AM DelMar Pharmaceuticals Announces Presentation at the European Association of Neuro-Oncology (EANO) Annual Meeting in October 2016
Jul 13, 2016 10:00AM DelMar Pharmaceuticals Inc. (Nasdaq: DMPI) to Ring The Nasdaq Stock Market Opening Bell
Jul 13, 2016 08:30AM DelMar Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell on July 14
Jul 11, 2016 09:13AM Delmar Pharma (DMPI) Approved to List on Nasdaq: Will Trade Under 'DMPI'
Jul 11, 2016 08:49AM DelMar Pharmaceuticals Announces Approval for Listing on NASDAQ
Jun 6, 2016 08:00AM DelMar Pharmaceuticals Presents Phase I/II GBM Clinical Trial Data and Outlines Future Clinical Development Plans at ASCO 2016 Annual Meeting
View More Recent Stories View Older Stories